Low-dose anlotinib confers improved survival in combination with immune checkpoint inhibitor in advanced non-small cell lung cancer patients
Shumin Yuan, Ling Peng, Yuqing Liu, Brian G. Till, Xiang Yan, Jie Zhang, Liping Zhu, Huijuan Wang, Shaokai Zhang, Hongle Li, Quanli Gao, Zibing Wang
Topics & Concepts
MedicineInternal medicineOncologyClinical endpointAdverse effectLung cancerTyrosine-kinase inhibitorUnivariate analysisCancerMultivariate analysisRandomized controlled trialLung Cancer Research StudiesCancer Immunotherapy and BiomarkersPeptidase Inhibition and Analysis